Literature DB >> 26274817

Changing Kidney Allograft Histology Early Posttransplant: Prognostic Implications of 1-Year Protocol Biopsies.

F G Cosio1,2, M El Ters3, L D Cornell2,4, C A Schinstock1,2, M D Stegall2,5.   

Abstract

Allograft histology 1 year posttransplant is an independent correlate to long-term death-censored graft survival. We assessed prognostic implications of changes in histology first 2 years posttransplant in 938 first kidney recipients, transplanted 1999-2010, followed for 93.4 ± 37.7 months. Compared to implantation biopsies, histology changed posttransplant showing at 1 year that 72.6% of grafts had minor abnormalities (favorable histology), 20.2% unfavorable histology, and 7.2% glomerulonephritis. Compared to favorable, graft survival was reduced in recipients with unfavorable histology (hazards ratio [HR] = 4.79 [3.27-7.00], p < 0.0001) or glomerulonephritis (HR = 5.91 [3.17-11.0], p < 0.0001). Compared to unfavorable, in grafts with favorable histology, failure was most commonly due to death (42% vs. 70%, p < 0.0001) and less commonly due to alloimmune causes (27% vs. 10%, p < 0.0001). In 80% of cases, favorable histology persisted at 2 years. However, de novo 2-year unfavorable histology (15.3%) or glomerulonephritis (4.7%) related to reduced survival. The proportion of favorable grafts increased during this period (odds ratio = 0.920 [0.871-0.972], p = 0.003, per year) related to fewer DGF, rejections, polyoma-associated nephropathy (PVAN), and better function. Graft survival also improved (HR = 0.718 [0.550-0.937], p = 0.015) related to better histology and function. Evolution of graft histologic early posttransplant relate to long-term survival. Avoiding risk factors associated with unfavorable histology relates to improved histology and graft survival. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Clinical research/practice; glomerular biology and disease; graft survival; kidney transplantation/nephrology; pathology/histopathology; protocol biopsy; translational research/science

Mesh:

Year:  2015        PMID: 26274817     DOI: 10.1111/ajt.13423

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  17 in total

1.  Protocol biopsies in pediatric renal transplantation: a precious tool for clinical management.

Authors:  Federica Zotta; Isabella Guzzo; Federica Morolli; Francesca Diomedi-Camassei; Luca Dello Strologo
Journal:  Pediatr Nephrol       Date:  2018-07-06       Impact factor: 3.714

2.  Relationships among injury, fibrosis, and time in human kidney transplants.

Authors:  Jeffery M Venner; Konrad S Famulski; Jeff Reeve; Jessica Chang; Philip F Halloran
Journal:  JCI Insight       Date:  2016-01-21

Review 3.  Kidney Fibrosis: Origins and Interventions.

Authors:  Thomas Vanhove; Roel Goldschmeding; Dirk Kuypers
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

4.  Preventive effect of early introduction of everolimus and reduced-exposure tacrolimus on renal interstitial fibrosis in de novo living-donor renal transplant recipients.

Authors:  Hiroaki Ishida; Go Ogura; Saeko Uehara; Shinya Takiguchi; Yousuke Nakagawa; Naoto Hamano; Masahiro Koizumi; Takehiko Wada; Masafumi Fukagawa; Michio Nakamura
Journal:  Clin Exp Nephrol       Date:  2019-12-02       Impact factor: 2.801

Review 5.  Current status of pediatric renal transplant pathology.

Authors:  Jan U Becker
Journal:  Pediatr Nephrol       Date:  2016-05-24       Impact factor: 3.714

6.  Automated Computational Detection of Interstitial Fibrosis, Tubular Atrophy, and Glomerulosclerosis.

Authors:  Brandon Ginley; Kuang-Yu Jen; Seung Seok Han; Luís Rodrigues; Sanjay Jain; Agnes B Fogo; Jonathan Zuckerman; Vighnesh Walavalkar; Jeffrey C Miecznikowski; Yumeng Wen; Felicia Yen; Donghwan Yun; Kyung Chul Moon; Avi Rosenberg; Chirag Parikh; Pinaki Sarder
Journal:  J Am Soc Nephrol       Date:  2021-02-23       Impact factor: 10.121

7.  Urinary vitronectin identifies patients with high levels of fibrosis in kidney grafts.

Authors:  Laura Carreras-Planella; David Cucchiari; Laura Cañas; Javier Juega; Marcella Franquesa; Josep Bonet; Ignacio Revuelta; Fritz Diekmann; Omar Taco; Ricardo Lauzurica; Francesc Enric Borràs
Journal:  J Nephrol       Date:  2020-12-04       Impact factor: 3.902

Review 8.  Recurrence of primary glomerulonephritis: Review of the current evidence.

Authors:  Fedaey Abbas; Mohsen El Kossi; Jon Kim Jin; Ajay Sharma; Ahmed Halawa
Journal:  World J Transplant       Date:  2017-12-24

9.  Multicentre randomised controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipients.

Authors:  Julie Ho; Atul Sharma; Kristine Kroeker; Robert Carroll; Sacha De Serres; Ian W Gibson; Patricia Hirt-Minkowski; Anthony Jevnikar; S Joseph Kim; Greg Knoll; David N Rush; Chris Wiebe; Peter Nickerson
Journal:  BMJ Open       Date:  2019-04-11       Impact factor: 2.692

10.  Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial.

Authors:  Tomas Reischig; Martin Kacer; Petra Hruba; Hana Hermanova; Ondrej Hes; Daniel Lysak; Stanislav Kormunda; Mirko Bouda
Journal:  BMC Infect Dis       Date:  2018-11-15       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.